Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2753 |
id |
doaj-227c9523685444d2b060406e9ec5b0b2 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giovanni Centonze Davide Biganzoli Natalie Prinzi Sara Pusceddu Alessandro Mangogna Elena Tamborini Federica Perrone Adele Busico Vincenzo Lagano Laura Cattaneo Gabriella Sozzi Luca Roz Elia Biganzoli Massimo Milione |
spellingShingle |
Giovanni Centonze Davide Biganzoli Natalie Prinzi Sara Pusceddu Alessandro Mangogna Elena Tamborini Federica Perrone Adele Busico Vincenzo Lagano Laura Cattaneo Gabriella Sozzi Luca Roz Elia Biganzoli Massimo Milione Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups Cancers lung cancer lung neuroendocrine neoplasm in silico analysis |
author_facet |
Giovanni Centonze Davide Biganzoli Natalie Prinzi Sara Pusceddu Alessandro Mangogna Elena Tamborini Federica Perrone Adele Busico Vincenzo Lagano Laura Cattaneo Gabriella Sozzi Luca Roz Elia Biganzoli Massimo Milione |
author_sort |
Giovanni Centonze |
title |
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups |
title_short |
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups |
title_full |
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups |
title_fullStr |
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups |
title_full_unstemmed |
Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups |
title_sort |
beyond traditional morphological characterization of lung neuroendocrine neoplasms: in silico study of next-generation sequencing mutations analysis across the four world health organization defined groups |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-09-01 |
description |
Lung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, <i>TP53</i> and <i>RB1</i> tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment. |
topic |
lung cancer lung neuroendocrine neoplasm in silico analysis |
url |
https://www.mdpi.com/2072-6694/12/10/2753 |
work_keys_str_mv |
AT giovannicentonze beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT davidebiganzoli beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT natalieprinzi beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT sarapusceddu beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT alessandromangogna beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT elenatamborini beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT federicaperrone beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT adelebusico beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT vincenzolagano beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT lauracattaneo beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT gabriellasozzi beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT lucaroz beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT eliabiganzoli beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups AT massimomilione beyondtraditionalmorphologicalcharacterizationoflungneuroendocrineneoplasmsinsilicostudyofnextgenerationsequencingmutationsanalysisacrossthefourworldhealthorganizationdefinedgroups |
_version_ |
1724575968707739648 |
spelling |
doaj-227c9523685444d2b060406e9ec5b0b22020-11-25T03:30:22ZengMDPI AGCancers2072-66942020-09-01122753275310.3390/cancers12102753Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined GroupsGiovanni Centonze0Davide Biganzoli1Natalie Prinzi2Sara Pusceddu3Alessandro Mangogna4Elena Tamborini5Federica Perrone6Adele Busico7Vincenzo Lagano8Laura Cattaneo9Gabriella Sozzi10Luca Roz11Elia Biganzoli12Massimo Milione131st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyMolecular Biotechnology and Bioinformatics, Department of Biosciences, University of Milan, Via Festa del Perdono 7, 20122 Milan, ItalyMedical Oncology Department, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyMedical Oncology Department, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyInstitute for Maternal and Child Health—IRCCS Burlo Garofolo, Via dell’Istria 65, 34137 Trieste, Italy2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS—Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyTumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyTumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyUnit of Medical Statistics, Biometry and Bioinformatics “Giulio A. Maccacaro”, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, ItalyLung neuroendocrine neoplasms (LNENs) represent a rare and heterogeneous population of lung tumors. LNENs incidence rate has increased dramatically over the past 30 years. The current World Health Organization LNENs classification (WHO 2015), distinguished four LNENs prognostic categories, according to their morphology, necrosis amount and mitotic count: typical carcinoid (TC), atypical-carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). At present, due to their rarity and biological heterogeneity there is still no consensus on the best therapeutic approach. Next-generation-sequencing analysis showed that WHO 2015 LNENs classes, could be characterized also by specific molecular alterations: frequently mutated genes involving chromatin remodeling and generally characterized by low mutational burden (MB) are frequently detected in both TC and AC; otherwise, <i>TP53</i> and <i>RB1</i> tumor suppressor genes alterations and high MB are usually detected in LCNEC and SCLC. We provide an overview concerning gene mutations in each WHO 2015 LNENs class in order to report the current LNENs mutational status as potential tool to better understand their clinical outcome and to drive medical treatment.https://www.mdpi.com/2072-6694/12/10/2753lung cancerlung neuroendocrine neoplasmin silico analysis |